Nav: Home

Age-related macular degeneration before and after the era of anti-VEGF drugs

May 02, 2016

In a study of nearly 650 people with the eye disease age-related macular degeneration (AMD), half still had vision 20/40 or better, typically good enough to drive or to read standard print, after five years of treatment with anti-VEGF drugs that are injected into the eye. The authors of the study, funded by the National Eye Institute (NEI) at the National Institutes of Health, say those outcomes would have been unimaginable about 10 years ago, prior to the drugs' availability.

The results were published in the journal Ophthalmology and presented May 2nd at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Seattle.

"This is the most comprehensive study of anti-VEGF therapy for AMD to date," said NEI Director Paul A. Sieving, M.D., Ph.D. "It points to the importance of long-term follow-up in studies evaluating disease treatments."

AMD is the leading cause of vision loss among older Americans. It causes damage to the central part of the retina, the light-sensitive tissue at the back of the eye. AMD often has very few symptoms in its early stages; but in later stages, it causes loss of the central, straight-ahead vision needed for activities like reading and driving.

There are two types of late AMD--geographic atrophy, and the more common neovascular AMD, also known as wet AMD. In neovascular AMD, fragile blood vessels grow under the retina and leak fluid. This usually starts in one eye, and is stimulated by a protein called VEGF. Just 10 years ago, people diagnosed with neovascular AMD were almost certain to develop severe vision loss in their affected eye and likely to lose vision in their other eye, too.

The new study looked at people with AMD who had regular treatment with drugs designed to block VEGF. After five years, 50 percent of them had 20/40 vision or better, 20 percent had 20/200 vision or worse, and the rest were in-between.

Ten years ago, the best available treatment for AMD was photodynamic therapy--in which an intravenous drug (injected into a vein) and laser are used to seal off leaking blood vessels. Past studies have found that just one year after diagnosis, less than 15 percent of patients given this therapy alone retain 20/40 vision, and up to 40 percent decline to 20/200 vision. Without any treatment, less than 10 percent of patients retain 20/40 vision at one year, and up to 75 percent of untreated patients decline to 20/200 vision.

In the U.S., state drivers' licenses generally require 20/40 vision in at least one eye. A best-corrected vision of 20/200 in both eyes is considered legally blind for the purpose of federal disability benefits.

The Comparison of AMD Treatments Trials (CATT) began in 2008 and was designed to compare the anti-VEGF drugs Avastin and Lucentis. VEGF is important in the growth and development of new blood vessels in normal and cancerous tissues. Avastin (bevacizumab) was approved by the Food and Drug Administration in 2004 for the treatment of metastatic colon cancer. Other drugs were later developed specifically to target blood vessels in the retina, with Lucentis (ranibizumab) coming to the market in 2006 and Eylea (aflibercept) in 2011. For treating AMD, the drugs are injected into the eye. Before Lucentis was available, many ophthalmologists began treating the disease with Avastin, which appeared to have similar benefits, at least in the short-term. The difference in the cost of the drugs also made Avastin appealing; the approximate per-dose price was $50 for Avastin and $2000 for Lucentis.

In the trial, more than 1200 participants with neovascular AMD were randomly assigned to receive either Lucentis or Avastin for two years, through monthly or as-needed injections. During that time, the two drugs were equally effective at preserving visual acuity. These results were later confirmed in five multicenter clinical trials around the world.

The current study followed up with CATT participants between March 2014 and 2015, an average of 5.5 years after enrollment in the trial. After two years on their assigned drug, participants were free to work with their eye care providers to choose their own course of therapy. During that 3.5-year period, more than half received at least one treatment with a drug or therapy other than the drug assigned to them. The investigators obtained visual acuity measurements for 647 of 914 participants who were still living.

In addition to the overall effects of anti-VEGF therapy at five years, the investigators compared the outcomes of participants who received Avastin or Lucentis during the trial.

"Some experts had speculated that two years of treatment with ranibizumab might have long-term benefits superior to bevacizumab. However, at five years, there were no differences in visual acuity between the two drugs," said Daniel F. Martin, M.D., chair of the Cleveland Clinic Cole Eye Institute and CATT study chair.

The study also found that after five years, participants assigned to Lucentis during the trial had a higher rate of strokes and heart attacks (7.6 percent) than those assigned to Avastin (4.5 percent). Since most participants received treatments other than their assigned drug after the two year-trial, the investigators are cautious about attributing this difference to the study drugs.

Finally, the study provides information on the general course of AMD with treatment. It was already known that many people with neovascular AMD eventually develop geographic atrophy, which has no treatment. In the trial, participants were more likely to develop geographic atrophy when they received monthly, rather than as-needed injections of Avastin or Lucentis. After the trial, almost all participants stopped monthly injections in favor of as-needed treatment, with an average of 4-5 injections per year. By five years, the rate of geographic atrophy increased from 20 percent of participants at two years to 41 percent at five years. The fraction of participants with geographic atrophy was similar between the Avastin and Lucentis groups.

"Although anti-VEGF treatment has greatly improved the prognosis for patients overall, we still need to find ways to avoid poor vision in these patients and to decrease the burden of ongoing treatment," said Maureen G. Maguire, Ph.D., the study's principal investigator and a professor of ophthalmology in the Perelman School of Medicine at the University of Pennsylvania in Philadelphia.
The CATT studies were supported by cooperative agreements EY017823, EY017825, EY017826, and EY017828 from NEI. For more information, visit (NCT00593450).

For more information about AMD, please see


CATT Research Group. Five-year outcomes with anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. May 2, 2016.

NEI leads the federal government's research on the visual system and eye diseases. NEI supports basic and clinical science programs that result in the development of sight-saving treatments and address special needs of people with vision loss. For more information, visit

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit

NIH...Turning Discovery Into Health®

NIH/National Eye Institute

Related Blood Vessels Articles:

Study: Use of prefabricated blood vessels may revolutionize root canals
Researchers at OHSU in Portland, Oregon, have developed a process by which they can engineer new blood vessels in teeth, creating better long-term outcomes for root canal patients and clinicians.
New findings on formation and malformation of blood vessels
In diseases like cancer, diabetes, rheumatism and stroke, a disorder develops in the blood vessels that exacerbates the condition and obstructs treatment.
Targeting blood vessels to improve cancer immunotherapy
EPFL scientists have improved the efficacy of cancer immunotherapy by blocking two proteins that regulate the growth of tumor blood vessels.
Reprogrammed blood vessels promote cancer spread
Tumor cells use the bloodstream to spread in the body.
Neurons modulate the growth of blood vessels
A team of researchers at Karlsruhe Institute of Technology shake at the foundations of a dogma of cell biology.
Sensor for blood flow discovered in blood vessels
The PIEZO1 cation channel translates mechanical stimulus into a molecular response to control the diameter of blood vessels.
Blood vessels control brain growth
Blood vessels play a vital role in stem cell reproduction, enabling the brain to grow and develop in the womb, reveals new UCL research in mice.
No blood vessels without cloche
After 20 years of searching, scientists discover the mystic gene controlling vessel and blood cell growth in the embryo.
New way of growing blood vessels could boost regenerative medicine
Growing tissues and organs in the lab for transplantation into patients could become easier after scientists discovered an effective way to produce three-dimensional networks of blood vessels, vital for tissue survival yet a current stumbling block in regenerative medicine.
Regenerating blood vessels gets $2.7 million grant
Biomedical engineers in the Cockrell School of Engineering at The University of Texas at Austin have received $2.7 million in funding to advance a treatment that regenerates blood vessels.

Related Blood Vessels Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...